GLP-1 Providers That Offer Tirzepatide Tablets (Verified 2026)

Published August 11, 2026 · Last verified: August 11, 2026

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. For information only — this is not medical advice.

Disclosure: We may earn a commission from some links on this page. It does not change what you pay. A relationship cannot erase an FDA warning letter, an unnamed pharmacy, a price conflict, or missing human evidence. MEDVi is an affiliate partner. We do not recommend it on this page, and we tell you why.

---

The GLP-1 providers that offer tirzepatide tablets on a live public page right now are Lavender Sky Health, Strut Health, Curex, GoodGirlRx, PlexusDx, Fitish RX, Henry Meds, SkinnyRx, MEDVi, Emerge Weight Loss, NexLife, Zealthy, Willow, TelehealthFX, Remote Pharmacy, Tru2U, Revel Health, and DietDoc.

They're real programs with real intake or checkout paths. But here's the part almost nobody puts above the fold: not one is selling an FDA-approved tirzepatide tablet, because no such product exists. FDA-approved tirzepatide — Zepbound and Mounjaro — is an injection only. Every oral tirzepatide product in the register below is advertised as compounded, which means the finished medicine was not reviewed and approved by the FDA before sale.

We found no peer-reviewed human study of the plain compounded ODTs, lozenges, sublingual tablets, or capsules sold by these 18 programs. We did find one registered human study of oral tirzepatide made with a patented delivery system called DehydraTECH. No provider in this register says it uses that system, and the company-reported tirzepatide arm did not show average weight loss over 12 weeks.

The lowest clear day-one charge we verified is $149 at Emerge Weight Loss for a 30-tablet ODT plan. Revel Health also advertises $149 for the first month, then a higher renewal price. The clearest pharmacy disclosure is still Lavender Sky Health, which names Empower for its ODT and Strive for its sublingual option before you pay.

And there's one more thing you need to know, because it changes the whole decision: since April 1, 2026, an FDA-approved GLP-1 tablet made by Eli Lilly has been available. It is called Foundayo. It contains orforglipron, not tirzepatide, and the medicine starts at $149 a month through Lilly's self-pay program. Through Ro, the first month starts at $188 before tax or fees because Ro charges a separate $39 first-month membership.

You were right that a GLP-1 pill exists. You were one molecule off. Let us show you the whole picture.

---

Checked on August 11, 2026, by hand:

• Every provider's current public product, price, terms, state, pharmacy, and disclaimer pages we could find
• FDA warning letters for Strut, GoodGirlRx, Curex, Fitish RX, SkinnyRx, MEDVi, NexLife, and Zealthy
• The FDA's March 3, 2026 announcement covering 30 telehealth warning letters
• The FDA's current page on unapproved GLP-1 drugs and adverse-event reports
• FDA-approved labeling for Zepbound, Mounjaro, Foundayo, and the Wegovy tablet
• PubMed and ClinicalTrials.gov searches for tirzepatide plus oral, sublingual, buccal, ODT, lozenge, troche, capsule, and rapid-dissolve terms
• The public registry and company-reported results for Lexaria's DehydraTECH oral-tirzepatide study
• Lilly's current Foundayo and Zepbound self-pay terms
• Ro's current membership and medication prices
• The public docket and complaint in Day v. OpenLoop Health Inc. et al.

What the public pages still do not settle:

• The order-specific dispensing pharmacy for most programs
• A single correct state-exclusion list for Curex; its own page gives two different lists
• A single correct one-, three-, and six-month tirzepatide-pill price table for GoodGirlRx; its product page and help center conflict
• Whether PlexusDx's three- and six-month rates are prepaid in full or billed monthly
• Whether Henry Meds' oral-tirzepatide package is a three-month or six-month supply; its own legal page says both
• MEDVi's exact current tirzepatide-tablet price; its public page advertises GLP-1 tablets from $249 without tying that figure to tirzepatide
• The full state list, pharmacy, and exact checkout terms for several newer programs
• Any public FDA close-out letter for the eight warning letters in this register. FDA says later interactions can change the status of issues described in warning letters.

We did not buy anything, take a consultation, or test a tablet. A price on a provider page is labeled provider-stated. An FDA approval, warning letter, label fact, or court filing is labeled officially verified. Our arithmetic is labeled calculated. Anything the public record cannot settle is labeled unresolved.

Corrections belong on the record. Use our corrections page if a provider page changes or a document we missed answers an unresolved field.

---

At least 18 telehealth programs had a live public page advertising a compounded tirzepatide tablet, orally disintegrating tablet, sublingual tablet, lozenge, or capsule on August 11, 2026. A one-month or first-month charge runs from $149 to $699 where a clear short plan is published. A multi-month prepayment can reach $3,492. None of these finished products is FDA-approved, and a live checkout page is not evidence that the product works.

We scored public transparency — what a shopper can verify before paying. We did not score results, safety, or medical quality. Nobody has published a peer-reviewed human study of the commercial dosage forms in this register.

⚑ = an FDA warning letter, a current marketing-claim conflict, a price or term contradiction, or more than one of those. The score is eight checkable public fields, not a quality or safety rating. A provider can publish a lot and still make a claim that should stop you.

Look at the fourth column again

That's the one most comparison pages still skip. Providers advertise a monthly average. You pay a real amount today.

• Lavender Sky's lowest ODT works out to $147.50 a month, but the first charge is $360 after its $65 initial consult.
• GoodGirlRx advertises $291 a month, but that rate means $3,492 upfront.
• Henry Meds puts $891 or $1,047 on the card before its own page settles whether the package covers three months or six.
• NexLife advertises $199 a month on its 12-month plan, but the first payment is $2,388.
• Revel's $149 is an intro month. The public page says the later rate starts at $199.

A lower monthly average is not always a lower risk. Sometimes it is a bigger check.

“Tablet” means different things on these pages

The words are not interchangeable, and providers use them loosely:

• ODT — orally disintegrating tablet. It breaks apart in the mouth.
• Sublingual — meant to sit under the tongue.
• Buccal — meant to sit against the inside of the cheek.
• Lozenge or troche — dissolves slowly in the mouth.
• Capsule or swallowed tablet — goes into the stomach.

Only follow the label on the medicine the dispensing pharmacy sends you. We do not give dosing or administration instructions here, and no comparison page should.

A live checkout proves one thing only

It proves the company is selling something. It does not prove the product works. It does not prove the pharmacy can ship to your state. It does not prove your prescription meets federal and state compounding rules. It does not prove the label will name the real compounder.

Before you pick a row, use the decision table on this page. Start with your one non-negotiable: FDA approval, no needle, tirzepatide itself, lowest first payment, named pharmacy, or no prepayment.

→ Jump to “Which tirzepatide tablet provider should I choose?”

---

No. As of August 11, 2026, there is no FDA-approved tirzepatide tablet, capsule, ODT, lozenge, troche, or drop. The FDA has approved tirzepatide as Zepbound and Mounjaro, and both are injections. Every oral tirzepatide product in this register is compounded, so the FDA did not review that finished product for safety, effectiveness, or quality before it was sold.

What “compounded” actually means

A compounding pharmacy can make a medicine for a patient with a medical need that an approved product cannot meet. That is a real and useful part of medicine. A person may need a different ingredient, strength, or dosage form.

But here is the line that costs people money: the pharmacy and the finished medicine are not the same thing. A traditional 503A pharmacy is licensed mainly through a state board of pharmacy, and the FDA may inspect or take action under federal law. A 503B outsourcing facility registers with the FDA and has more federal requirements, including FDA inspection and adverse-event reporting. Neither path turns a compounded finished drug into an FDA-approved drug.

So “made in an FDA-registered facility” does not mean “FDA-approved medicine.” It may describe a 503B facility. It does not mean the FDA approved the tablet in your bottle.

The shortage rule changed

The FDA determined on December 19, 2024 that the tirzepatide injection shortage was resolved. After a federal court denied a request to block that decision on March 5, 2025, the FDA's shortage-based enforcement period ended for 503A compounders and ended March 19, 2025 for 503B outsourcing facilities.

That did not ban every patient-specific tirzepatide compound. It did close the broad shortage-copy lane. A 503A compound still has to meet all conditions that apply to that prescription, including the rule against routinely making a drug that is essentially a copy of an available approved product. A prescriber may decide that a patient needs a different dosage form, but “different route” is not a magic word that makes every online tablet lawful.

The honest answer to “is this legal?” is not yes or no for the whole category. It depends on the exact prescription, the compounder, the ingredients, the medical reason, and the federal and state rules that apply.

Six phrases that should stop you cold

The FDA has publicly objected to these kinds of claims in warning letters and agency statements:

1. “Generic Zepbound”
2. “Same as Zepbound”
3. “The same active ingredient as an FDA-approved GLP-1” when used to imply sameness or approval
4. “Clinically proven oral tirzepatide”
5. “Zepbound results without needles”
6. “No prescription needed”

Eight providers in the register have an FDA warning letter. Seven letters expressly discuss tirzepatide marketing. Zealthy's letter discusses compounded semaglutide marketing, not its current tirzepatide capsule offer.

A warning letter is not a recall, a shutdown, or proof that a medicine injured someone. It is a formal FDA notice about cited violations. It belongs in the decision because it tells you how a company marketed unapproved compounded medicine.

---

No reliable answer exists yet for the products in this register. We found no peer-reviewed human study that measured the absorption, weight loss, or safety of the plain compounded ODTs, lozenges, sublingual tablets, or capsules sold by these providers. Injection trial results cannot answer that question because an injection and a mouth-dissolving product are different finished medicines delivered by different routes.

This is the section we would want to read before spending $891, so we are going to be plain about it.

What we searched, so you can repeat it

On August 11, 2026, we searched PubMed and ClinicalTrials.gov for:

tirzepatide AND (oral OR sublingual OR buccal OR “orally disintegrating” OR ODT OR lozenge OR troche OR capsule OR “rapid dissolve”)

What we found for the commercial forms in this register: no peer-reviewed human absorption or weight-loss study.

We found one registered human study that used oral tirzepatide with a special delivery platform called DehydraTECH. That is not a plain ODT or lozenge. It is a patented processing system. No provider in our register says its product uses it.

We also found preclinical work, including animal or lab delivery systems. That is useful research. It cannot tell you what a telehealth tablet does in a person.

Empower Pharmacy — which makes the ODT Lavender Sky lists — says on its own product page that the preparation is not FDA-approved and has not gone through clinical trials. The maker says it. We are not adding drama to it.

The absorption number nobody has measured for these products

Here is where it gets strange, and this is the part most sales pages skip.

Bioavailability is the share of a dose that reaches the bloodstream. We collected the figures other websites publish for oral or sublingual tirzepatide and checked what each number was based on.

Read the figures top to bottom. The guesses run from 0.1% to 18%. That is a 180-fold spread.

And one website publishes 11%–18% on one page and 3%–8% on another. Those are not two tirzepatide studies fighting over a small difference. They are estimates built from other products.

That means the figure is not proof. It is not a dose-conversion tool. It is not a reason to claim the tablet will match Zepbound.

One company did get oral tirzepatide into the blood

We want to be fair, so here is the exception.

Lexaria Bioscience reported a small eight-day pilot in 2025. Nine people received tirzepatide processed with its patented DehydraTECH system, and ten received injected Zepbound. The company said the oral group reached roughly similar end-of-study blood levels and reported fewer adverse events. That was company-reported, very small, and not a test of any product in our register.

Lexaria then ran a registered Phase 1b study, NCT06648031, that included 25 people in a DehydraTECH-tirzepatide arm. In the company's final 12-week report, tirzepatide remained measurable in blood, but the group had an average 0.67 kg weight gain at week 12, not weight loss. The company said its DehydraTECH-semaglutide result — not its tirzepatide result — was the part most worthy of more study.

So oral delivery is not impossible.

But look at what it took: a purpose-built delivery system. And even then, getting some drug into blood did not equal average weight loss in that small company-reported arm.

If anything, that result makes the sales-page certainty harder to defend. “Absorbed” and “works for weight loss” are not the same claim.

Why reviews cannot settle this

You will find people online who say their tablets worked. You will find people who say nothing happened.

Those posts tell you what buyers are worried about. They cannot tell you average absorption, average weight loss, or safety. There is no control group. The product may differ by pharmacy. The dose may differ. People who are happy may post more, and people who are angry may post more.

Reviews are useful for service facts: Did the package arrive? Did support answer? Was cancellation hard? Keep reviews in that lane.

---

No. There is no validated conversion from a compounded oral tirzepatide dose to a Zepbound or Mounjaro injection dose. You can add the raw milligrams printed on public pages, but you cannot turn a guessed absorption rate into a clinical equivalent. Any chart that tells you a tablet “equals” a certain injection dose is pretending to know what has not been measured.

Nobody else does the arithmetic carefully, so we did — and then we stopped where the evidence stops.

The setup, in plain numbers

• FDA-approved injected tirzepatide is dosed once weekly from 2.5 mg to 15 mg. The 2.5 mg dose is for starting treatment, not maintenance.
• The Zepbound label reports mean absolute bioavailability of about 80% after a subcutaneous injection.
• Lavender Sky's Empower ODT page lists a 3 mg daily starting tier and higher daily amounts by tier. Henry Meds says “up to 6 mg” daily.
• A 3 mg daily product places 21 mg a week in the mouth.
• A 6 mg daily product places 42 mg a week in the mouth.

That looks like more raw drug than a 15 mg weekly injection. It still does not tell you how much enters the blood, how fast it enters, how long it stays there, or what effect it has.

What the internet guesses would mean as arithmetic only

Using 3 mg a day — 21 mg a week — here is the multiplication:

The table proves one thing: an unmeasured input can create any answer you want. At the high guess, the number looks meaningful. At the low guess, it looks tiny. Neither side is measured evidence for a tablet in this register.

Read this before you trust our math

We are holding ourselves to the same standard we use for providers:

• This is arithmetic on other people's estimates. It is not a measurement of any product.
• The 80% figure belongs to the approved injection. It cannot be pasted onto an oral dosage form.
• Blood amount is not the same as clinical effect. Peak level, total exposure, timing, metabolism, and receptor activity matter.
• There is no validated oral-to-injection conversion. A prescriber should not use this table to set a dose.
• Henry Meds' “up to 6 mg” sits inside a page that also conflicts on the supply length. That makes it a poor anchor for anything beyond showing the raw-milligram problem.

What the FDA said about dose errors

The FDA says it has received reports tied to compounded semaglutide and tirzepatide doses beyond approved labels, including taking more in one dose, taking doses more often, or increasing too quickly.

That does not prove every prescribed daily oral formulation is unsafe. A daily oral product is not automatically the same as an accidental extra injection. It does show why a seller should not hand you a homemade injection-equivalence chart when the route has never been validated.

If the tirzepatide molecule is the thing you will not give up, you do not have to guess about the route. Zepbound is the FDA-approved version studied in people. Current self-pay pricing starts at $299 for 2.5 mg and can be $449 for 7.5–15 mg when the refill offer applies.

→ Check Zepbound pricing and coverage on Ro

Ro charges a separate membership. The first month is $39, then $74–$149 a month depending on the plan. Medication is billed separately.

---

The lowest clear one-month tirzepatide ODT price we verified is $149 at Emerge Weight Loss. Revel Health also charges $149 for the first month, then says renewal starts at $199. Clear short-plan prices run up to $699 at DietDoc. Multi-month prepayment can reach $3,492 at GoodGirlRx. The number that matters is what hits your card today, what renews next, and what happens if the clinician says no.

This is where most shoppers get caught, so we broke it down properly.

Headline price vs. what hits your card

The GoodGirlRx conflict is bigger than two dollars

The live product page says:

• 1 month: $397
• 3 months: $345 a month
• 6 months: $312 a month
• 12 months: $291 a month

Its help center says:

• 1 month: $399
• 3 months: $798 total, or $266 a month
• 6 months: $1,482 total, or $247 a month
• 12 months: $3,492 total, or $291 a month

The 12-month total matches. The other rows do not. We are not choosing one page for the company. Get the exact total in writing before you enter a card.

The line we did not expect to rewrite

The old version of this page said the cheapest approved GLP-1 pill cost less than every compounded tirzepatide tablet. That is no longer true.

Foundayo starts at $149 drug-only. Emerge also starts at $149, and Revel uses $149 as a first-month offer. Through Ro, Foundayo's first-month total starts at $188 because the $39 membership is separate.

So the clean comparison is not “approved is cheaper.” It is this:

• Emerge: $149 for a compounded ODT, no peer-reviewed route-specific human evidence found.
• Revel: $149 intro for a compounded ODT, then from $199.
• Foundayo through Lilly self-pay: $149 for an FDA-approved finished tablet with human trials and an FDA label.
• Foundayo through Ro: $188 first month before tax or fees, including Ro's $39 first-month membership; medicine and membership stay separate after that.

At the same drug-only price, the approved product carries the evidence advantage. But the total telehealth bill still matters.

Things that may or may not be included

Ask before you pay. Programs vary on:

• The clinical consultation
• The medicine, if prescribed
• Shipping
• Follow-up messages with a clinician
• Dose changes
• Lab work
• A separate monthly membership
• A multi-month prepayment
• A refill deadline tied to a lower price

Lavender Sky charges its consult separately and has no monthly membership. Strut, PlexusDx, Fitish, Emerge, NexLife, and others describe medication and care as bundled, but each has different terms. Ro's medicine price is separate from its membership. A $149 medicine plus a $39 membership is a $188 first month.

What happens if the clinician says no?

Get five answers before you pay:

1. Is the consultation or intake fee refunded?
2. Do you charge the medicine before a clinician reviews me?
3. When does fulfillment begin?
4. Is a refund available if I am not prescribed the medicine?
5. Are administrative fees kept even when no medicine ships?

Revel says it refunds the first-month payment if you are not approved. Ro says its $39 first-month membership is refunded if you are not eligible for GLP-1 treatment. Do not assume every program works that way.

What happens after the intro price?

Get the renewal amount, auto-refill rule, refill timing, and cancellation deadline in writing before you enter a card. Strut's $199 price requires auto-refill. Remote Pharmacy's $229.99 first month becomes $349.99. Zealthy's $249 is presented as a discounted first month from $349. NexLife's lowest monthly average requires a long prepayment. MEDVi publishes a 72-hour cancellation rule for recurring billing.

None of that is the same as “hidden.” It is just not always beside the big number.

Run your own first-payment test before you enter a card. Write down today's charge, the next charge, the cancellation deadline, and the pharmacy name. If one box is blank, do not pay yet.

→ Take the free GLP-1 matching quiz

---

There is no evidence-based “best” tirzepatide tablet provider because nobody has published a peer-reviewed human study of the commercial oral forms. You can still choose between the facts that are visible. Emerge has the lowest clear month-to-month starting charge. Lavender Sky has the clearest pharmacy disclosure. Strut has a simple 30-day non-prepay option. Readers who need FDA approval, human evidence, or insurance should use a different route.

Find your row. Then read that provider's section.

A note for readers whose real requirement is “no needle”

If we are honest, “tirzepatide tablets” is often a search for no needle wearing a costume.

That matters because the answer does not have to contain tirzepatide. Foundayo and the Wegovy pill are FDA-approved tablets. Foundayo has no food-timing rule. The Wegovy tablet has a strict morning routine. Both have real human trial programs behind the exact finished route.

The first question is not “Which compounded tirzepatide tablet?” It is: Do you need tirzepatide, or do you need no needle? Those are different decisions.

→ Compare GLP-1 options without needles

---

Lavender Sky Health — the clearest pharmacy disclosure

The verdict: If you are going to buy a compounded tirzepatide tablet, this is the program where you can see the most important source detail before paying.

Lavender Sky does the one thing most competitors do not: it tells you the pharmacy and ties each pharmacy to a form and price. Its ODT comes from Empower Pharmacy. Its sublingual option comes from Strive Pharmacy.

That matters. With the legal pharmacy name, you can check the license on your state board of pharmacy site. You can compare the package label to what you were promised. You can call the pharmacy. Without the name, you cannot do any of that before money changes hands.

The numbers, verified August 11, 2026:

• Empower ODT, 60 days: $295, $345, or $395, depending on tier
• Strive sublingual tirzepatide, 60 days: $475, $525, or $625
• Initial consult: $65
• Follow-up consult: $40
• Lowest real first payment for the ODT: $360
• No monthly membership fee
• A separate pharmacy-by-state coverage page is public

Who it fits: someone who has talked with a clinician, has a patient-specific reason for a different form, and wants a source trail.

Who should skip it: anyone who needs FDA approval, insurance coverage, one-month testing, or a product with published human evidence.

The thing Lavender Sky does not hide, and neither will we: its plan page says the medicine is compounded and not FDA-approved. Empower's own tirzepatide ODT page says the preparation has not gone through clinical trials.

---

Strut Health — a simple 30-day commitment with an FDA letter

The verdict: A clear short plan for someone who refuses a multi-month prepayment, but the pharmacy is not named and the FDA warning letter must stay beside the price.

Strut lists a once-daily tirzepatide lozenge with vitamin B6 at $239 for 30 days. The rate drops to $199 when you accept auto-refill. The public price includes the provider review, prescription if appropriate, medication, shipping, and follow-up care.

Strut also frames the route around medical need. Its page says the oral option is for a person who cannot use or has not done well with an injection. That is a better frame than pretending every needle-free shopper automatically needs a compound.

But we have to flag this: Strut received FDA warning letter 721448, dated February 20, 2026. The FDA said Strut's site used labels that could make Strut look like the compounder and used claims such as “Generic Zepbound, Mounjaro” and active-ingredient language that implied the compounded products had been reviewed or approved when they had not.

A warning letter is not a recall, a shutdown, or proof that a medicine is unsafe. It is still a formal FDA finding about the marketing a shopper saw.

Unresolved before payment: dispensing pharmacy, full state list, and the exact auto-refill cancellation cutoff.

Who it fits: someone whose clinician documents why an injection is not workable and who wants 30 days instead of a prepay block.

Who should skip it: anyone who needs the pharmacy name before paying.

→ Check Strut's current oral-tirzepatide terms

---

Curex — a low sticker price with two state lists

The verdict: “From $199” is attractive, but the public page leaves the dose, renewal price, pharmacy, and even the state list unsettled.

Curex advertises a tirzepatide ODT from $199, with the medicine, prescription, shipping, and support included and no separate membership.

The same live page gives two different state-exclusion lists. One part excludes Alaska, Arkansas, Connecticut, Hawaii, Massachusetts, Missouri, and New Mexico. Another part says only Arkansas, Connecticut, and New Mexico are excluded.

That is not a small copy error. State availability decides whether the program can legally serve you.

The FDA sent Curex warning letter 716821 on September 9, 2025. The letter addressed compounded semaglutide and tirzepatide marketing, including claims that the products were clinically proven and language implying sameness with approved medicine.

Curex says a full refund is available when its clinician does not prescribe. Still, confirm when the charge happens and whether any fee is kept.

What you need in writing: your exact dose, your first total, your renewal total, the dispensing pharmacy, your state's actual status, and the cancellation cutoff before fulfillment.

We are not recommending Curex until those fields agree. Low price plus unknown dose plus unknown pharmacy is not a bargain. It is an unfinished invoice.

---

GoodGirlRx — clear prepayment, conflicting prices, and an FDA letter

The verdict: GoodGirlRx is unusually direct that its multi-month plans are prepaid, but two of its own current pages disagree on three of the four price rows.

The product page says:

• 1 month: $397
• 3 months: $345 a month
• 6 months: $312 a month
• 12 months: $291 a month

The help center says:

• 1 month: $399
• 3 months: $798 total
• 6 months: $1,482 total
• 12 months: $3,492 total

Only the twelve-month number matches across both pages. The product page also says the three-month plan saves $156 while listing a $52 monthly discount, which would equal $156, but that implied total does not match the help-center total.

GoodGirlRx advertises care across the United States and says HSA/FSA cards are accepted. It does not name the order-specific pharmacy on the product page.

The FDA sent GoodGirlRx warning letter 721449 on February 20, 2026. The letter covered compounded semaglutide and tirzepatide and cited brand-labeled product images plus claims such as “FDA-approved meds,” “FDA-approved options,” and “Clinically proven GLP-1 results.”

Who it fits: only someone who has the exact current checkout total, pharmacy, refund terms, and renewal terms in writing — and who understands that the route itself lacks peer-reviewed human evidence.

Who should skip it: anyone buying a compounded oral product for the first time. Do not pay $3,492 to discover in month two that it does nothing for you.

---

PlexusDx — more disclosure than most, plus a sameness problem

The verdict: PlexusDx publishes a lot of useful detail. Its “same active ingredient” language is still the exact kind of shortcut the FDA has challenged elsewhere.

PlexusDx lists:

• $349 month-to-month
• $299 a month on a three-month plan
• $279 a month on a six-month plan

The price includes the provider, prescription, compounded medicine, and shipping, with no separate membership. The page says care is available in all 50 states and says you can cancel anytime.

The missing field is payment timing. The public page does not make clear whether the three- and six-month options are prepaid in full or billed monthly. Get that answer before using the lower monthly number.

PlexusDx also says no published human study has measured oral tirzepatide absorption or efficacy. That is one of the clearest disclosures in the category.

But the same current page says its tablet uses “the same active ingredient” as Zepbound and Mounjaro. It also describes injection-derived mechanisms and outcomes beside the oral offer. Those claims do not prove the oral product produces the approved injection's results.

Unresolved: order-specific pharmacy and multi-month billing timing.

---

Fitish RX — a simple price with a current FDA letter

The verdict: The monthly number is easy to understand. The route-specific result claims are not supported by the evidence we found.

Fitish lists $339 for a monthly supply, with a medical evaluation required. The page describes the consultation, medication if prescribed, and shipping as part of the program.

The problem is the result copy. The page gives confident timelines for appetite change and visible weight progress and describes absorption and the “same active mechanism” without a human study of this oral product.

The FDA sent Fitish warning letter 728280 on June 8, 2026. The letter covered compounded semaglutide and tirzepatide marketing. That is a very recent regulatory fact and belongs next to the offer.

Unresolved: pharmacy, full state list, and complete cancellation terms.

A clean monthly price does not clean up an unsupported route claim.

---

Henry Meds — a familiar name with a three-month/six-month contradiction

The verdict: Henry publishes the total. Its own legal page does not settle what that total buys.

Henry's legal page labels the offer “Tirzepatide Oral (3-Month Supply)” and lists $1,047, or $891 if paid in full. The very next line says the medicine is delivered every 60 days for six months.

Those are not the same plan. If the package is three months, the $891 price averages $297 a month. If it is six months, it averages $148.50. The contradiction changes the apparent price by half.

There is no clear month-to-month test on that page. So the smallest published outlay is roughly $891.

Henry also does not name the dispensing pharmacy on the public program page.

Who it fits: someone who has already confirmed the exact product, supply period, pharmacy, refill schedule, and refund terms in writing.

Who should skip it: anyone who wants to spend less than $891 to find out whether an unstudied route does anything.

We are not publishing a normalized Henry monthly price until Henry's own terms agree.

---

SkinnyRx — the warning letter changed our answer

The verdict: We used to recommend this program. We do not anymore, and we owe you the reason.

SkinnyRx currently advertises once-daily compounded tirzepatide tablets from $299 a month, with shipping and HSA/FSA language on its public sales path.

On February 20, 2026, the FDA sent Lean Rx, Inc. dba SkinnyRx warning letter 717989. The FDA said the pictured label could make SkinnyRx look like the compounder when it was not. The letter also quoted claims saying the product was from the same family as Mounjaro and Zepbound and contained the same active ingredient as FDA-approved medicine.

The FDA's point was not that using the word “tirzepatide” is always forbidden. Its point was that the whole presentation could make an unapproved compounded product look evaluated or approved like the brands.

Being fair: the letter was about marketing and labeling. It was not a contamination finding, a recall, or a shutdown. FDA also warns that later interactions can change the status of issues in a warning letter.

Unresolved: any public close-out letter, the current pharmacy, full state coverage, final checkout total, and cancellation terms.

A full provider audit belongs at our SkinnyRx review.

---

MEDVi — a price category, not an exact tirzepatide price

The verdict: MEDVi sells GLP-1 tablets, but its public page does not tie the advertised “from $249” figure to a specific tirzepatide tablet, dose, or renewal. That is not enough for a recommendation.

The current landing page advertises GLP-1 tablets starting at $249. It does not clearly say that the $249 figure is the exact current price for tirzepatide rather than another tablet option.

MEDVi received FDA warning letter 721455 on February 20, 2026. The letter covered source labeling and sameness claims for compounded semaglutide and tirzepatide. MEDVi also publishes recurring-billing terms that require cancellation at least 72 hours before the next billing date.

Here is the uncomfortable part: MEDVi is an affiliate partner. We are not recommending it. A commission does not outrank an unclear product-specific price, an unnamed order pharmacy, and an FDA warning letter.

Unresolved: exact tirzepatide-tablet price, dose, order pharmacy, state list, and any public FDA close-out letter.

Our full breakdown is at our MEDVi review.

---

Emerge Weight Loss — the lowest clear monthly start

The verdict: Emerge has the lowest clean one-month ODT price we verified and makes a damaging admission most competitors avoid.

Emerge lists $149 for 30 tirzepatide ODT tablets, including the medical intake review, prescription if appropriate, ongoing provider access, and shipping. Its live page lists higher-strength plans at $199 and $249.

Then Emerge says the quiet part out loud: tablets and pills are not as effective as injected tirzepatide for weight loss, and people already using higher injection doses may lose meaningful effect by switching.

That is provider-stated, not a trial result. But it is a much more honest sales frame than “same Zepbound results without needles.”

The page says the medicine is compounded through a licensed 503A pharmacy. It does not name the order-specific pharmacy on the public product page.

Who it fits: someone whose clinician has a real reason for an oral compound, wants a one-month test, accepts the evidence gap, and cares most about the lowest clear first payment.

Who should skip it: anyone who needs FDA approval, insurance, a named pharmacy before payment, or an oral product proven to match the injection.

---

NexLife — transparent prepayment math with a June FDA letter

The verdict: NexLife shows the real prepaid totals, which is good. The recent FDA warning letter and long-plan risk still matter.

NexLife advertises sublingual tirzepatide ODT plans at:

• Monthly: $229
• Three months: $657 upfront, or $219 a month
• Six months: $1,230 upfront, or $205 a month
• Twelve months: $2,388 upfront, or $199 a month

The page says provider guidance, pharmacy coordination, shipping, nutrition guidance, and coaching are included. It also says NexLife does not manufacture or compound the medicine and that pharmacy, appearance, packaging, and labeling may vary.

The FDA sent NexLife warning letter 730096 on June 8, 2026. The letter addressed compounded semaglutide and tirzepatide marketing.

NexLife's public terms require advance notice for cancellation. Confirm the exact deadline for the plan you choose.

Who it fits: someone who wants a disclosed total and chooses the monthly option first.

Who should skip it: a first-time buyer considering the $2,388 prepayment. The lower average does not refund the months you do not want.

---

Zealthy — a $249 intro capsule with a semaglutide warning letter

The verdict: The intro number is clear. The page still leans on the approved brands to explain an unapproved capsule.

Zealthy advertises oral tirzepatide capsules at $249 for the first month, shown as $100 off a regular $349. It says medical care and supervision are included and states that the compounded medicine is not FDA-approved.

The same page calls tirzepatide “the active ingredient in Mounjaro and Zepbound.” In context, that can make the capsule feel closer to the approved products than the evidence allows.

Zealthy received FDA warning letter 716501 on September 9, 2025. That letter addressed compounded semaglutide marketing, not the current tirzepatide capsule page. We still show it because a reasonable shopper would want the provider's regulatory history, but we do not mislabel what the letter covered.

Unresolved: order pharmacy, full state list, final renewal terms, and any public close-out letter.

---

Willow — a clear $399 price and route-mixed testimonials

The verdict: Willow clearly publishes the price and non-FDA status. Its result copy and testimonials do not prove the tablet itself caused the outcomes shown.

Willow lists a daily dissolving tirzepatide tablet at $399 a month, says HSA/FSA cards are accepted, and states that the medicine is compounded and not FDA-approved.

The page says a Willow doctor personalizes the prescription and a licensed U.S. compounding pharmacy prepares it. The order-specific pharmacy is not named before payment.

The page also places broad tirzepatide claims and weight-loss testimonials around both tablet and injection content. Those stories may describe individual care experiences, but they do not measure the oral tablet's absorption or average effect.

Who it fits: someone who values a simple monthly price and has the pharmacy and route confirmed in writing.

Who should skip it: anyone reading the testimonials as tablet-specific clinical proof.

---

TelehealthFX — clear starting price, unsupported site-wide result claims

The verdict: Tirzepatide tablets start at $299 with no separate membership shown, but the site-wide result numbers cannot be assigned to this tablet.

TelehealthFX advertises daily sublingual tirzepatide tablets from $299 a month, with free two-day shipping and no hidden membership fee.

The broader site also publishes claims such as 94% of members losing weight in 90 days and an average 15-pound loss at three months. The public page does not show that those figures came from tirzepatide-tablet users, a controlled study, or even one dosage form.

That does not prove the numbers are fake. It means they cannot answer the oral-tirzepatide question.

Unresolved: exact starting dose, order pharmacy, first renewal total, full state list, and the evidence behind route-specific results.

---

Remote Pharmacy — a clear intro price with injection results pasted onto a tablet

The verdict: The payment schedule is clear. The product claims are not.

Remote Pharmacy lists:

• First month: $229.99
• Later monthly price: $349.99
• Three months: $950 total
• Six months: $1,800 total

The page says the medicine, provider consultation, pharmacy fulfillment, and shipping are included.

Then the page calls the product a “weekly tablet” in one place and gives daily under-the-tongue directions in another. It also says patients lose up to 15%–22% of body weight, which comes from tirzepatide evidence that does not establish the result of this tablet.

The page itself admits the product is not FDA-approved and has not been evaluated by the FDA for safety or effectiveness. That disclosure and the injection-like result claim do not sit well together.

Unresolved: pharmacy, state list, exact dose, and which schedule the label actually uses.

---

Tru2U — one page says both FDA-approved and not FDA-approved

The verdict: The price is clear. The safety answer contradicts the legal disclaimer on the same page.

Tru2U lists compounded oral tirzepatide tablets at $345 and says a licensed clinician must approve the program. It also explains that the Tru2U storefront redirects the medical process to an independent clinical partner.

Near the bottom, the page correctly says compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality.

But its FAQ also says: “All treatments are FDA-approved.” Both cannot be true for the product on that page.

That contradiction is enough to stop the purchase until the company fixes it in writing.

The page also gives a four-to-eight-week result timeline without route-specific human evidence.

Unresolved: which entity charges you, which entity prescribes, which pharmacy dispenses, the state list, and the exact refund path across the storefront and clinical partner.

---

Revel Health — a $149 first month with the clearest “not approved” refund

The verdict: Revel ties the lowest intro charge and publishes a clear refund statement if a clinician does not approve treatment.

Revel lists tirzepatide ODT at $149 for the first month, then from $199 a month. It says a licensed clinician reviews the questionnaire and offers a 100% refund if you are not approved.

Revel also says it is not a pharmacy, that product images are stylized, and that compounded GLP-1 medicines are not FDA-approved or evaluated for safety, quality, or efficacy.

That is useful disclosure.

The missing pieces are the order-specific pharmacy, exact dose, full state list, renewal by dose, and cancellation deadline after the first month.

Who it fits: someone testing a short plan who puts a strong refund-on-denial term above pharmacy transparency.

Who should skip it: anyone who needs the pharmacy name before payment or wants a proven oral route.

---

DietDoc — the highest short-plan price and a direct sameness claim

The verdict: $699 is the highest clear first-month oral price in our register, and the page makes a claim the evidence cannot support.

DietDoc lists compounded tirzepatide ODT at $699 for the first month. It correctly says the product is compounded and not FDA-approved.

But the same page says the ODT provides “the same therapeutic benefits as injections.” No peer-reviewed human study of this ODT establishes that. The page also says the mechanism is based on tirzepatide studies, which is true at the molecule level but does not prove the finished oral route performs like the approved injection.

Do not confuse DietDoc's ODT price with lower prices for its injectable plans. They are different products.

Unresolved: exact quantity, dose, renewal price, pharmacy, and state list.

At $699, the proof burden should be higher, not lower.

---

Programs removed from the active register

We checked other names and left them out when a current public page did not support the same intent:

• MyStart Health — we found a current general compounded GLP-1 offer, but not a current public oral-tirzepatide product page with enough detail to keep it in the active register.
• Gala GLP-1 — its current pill page says the new GLP-1 pills are “coming soon,” so it is not a current seller for this table.
• Any “tablet” page that now redirects to injections
• Any seller with no real clinician review step
• Any listing that will not identify the dosage form
• Any listing offering tirzepatide without a prescription

MyStart Health and Gala appeared as storefront names in exhibits to the proposed class-action complaint discussed below. That is an allegation in a lawsuit, not a finding, and it does not turn either company into a current active seller today.

---

A patient-specific compounded tirzepatide tablet may be lawful only when the prescription, prescriber, compounder, ingredients, and finished product meet every federal and state rule that applies. A live product page does not prove that. The FDA has sent warning letters to companies in this market, and a proposed nationwide class action over oral tirzepatide is pending in Delaware.

The honest answer is narrower than either sales pages or scare pages make it sound. Compounding is legal medicine. Routine copying and misleading marketing are not.

The 30 FDA warning letters

On March 3, 2026, the FDA announced 30 warning letters to telehealth companies over compounded GLP-1 marketing. The agency highlighted two repeated problems:

1. Claims that made an unapproved compounded drug sound the same as an FDA-approved product
2. Labels or images that hid the real source of the compounded drug by putting the telehealth company's name where the compounder's identity should be clear

Eight providers in our active register have a warning letter we verified:

A warning letter is not a finding that a medicine was contaminated. It is not a recall. It is not a final court judgment. It is still material. The FDA says its warning-letter database may not show every later interaction, so we checked for public close-out letters and found none for these eight as of August 11, 2026.

How to use this: look at any oral-tirzepatide sales page for two things. Does it say “same,” “generic,” or “clinically proven” by borrowing from the injection? Does the bottle carry the telehealth brand while the actual pharmacy stays hidden? That is the exact pattern the FDA has been calling out.

The proposed class action

A proposed class action, Day v. OpenLoop Health Inc., Triad Rx Buyer LLC, and Triad Rx Inc., was filed in the U.S. District Court for the District of Delaware on November 20, 2025.

The complaint alleges that oral tirzepatide products were sold as safe and effective alternatives without demonstrated absorption or effectiveness. It lists storefront names in its allegations and exhibits, including MEDVi, MyStart Health, Gala GLP-1, Fridays, Remedy Meds, Prime Health, FuturHealth, and others.

Here is the line that matters: the named defendants are OpenLoop and the two Triad entities. The storefronts shown in exhibits are not automatically named defendants. The complaint contains allegations, not findings. The public docket we reviewed shows motions to dismiss and compel arbitration were briefed in April 2026. We found no merits ruling, no class certification, and no judgment in that public docket view.

MEDVi pays us when some readers use our links. We are still telling you that its name appears in the complaint's storefront allegations and that it has an FDA warning letter. A commission does not make either fact disappear.

Retatrutide and cagrilintide are a different problem

The FDA has stated in an enforcement letter that retatrutide and cagrilintide are not eligible for use in compounding under section 503A because they are not components of FDA-approved drugs and have not been found safe and effective for a clinical use.

That is not the same legal question as patient-specific tirzepatide compounding. If a site bundles “oral tirzepatide,” retatrutide, and cagrilintide together as if all three sit in the same lane, the site is leaving out a major federal distinction.

---

Before paying for a compounded tirzepatide tablet, confirm the prescriber, the prescriber's state license, the exact dosage form, the dispensing pharmacy's legal name, the pharmacy's license to ship to you, your day-one and renewal charges, the cancellation deadline, and the patient-specific reason for using a compounded form. A polished website proves none of those things.

Give this twenty minutes. Do it in this order.

The 12 questions

1. Who is the licensed prescriber? Get a name and credential, not “our medical team.”
2. Is that prescriber licensed in my state?
3. What exact dosage form am I getting? ODT, sublingual tablet, buccal tablet, lozenge, troche, capsule, or swallowed tablet?
4. Which pharmacy will dispense my prescription? Get the exact legal name.
5. Is that pharmacy licensed to ship this prescription to my state?
6. Will you give me the pharmacy name before you charge me for medicine?
7. What will you charge today, exactly?
8. What is the next charge, and on what date?
9. Am I agreeing to auto-refill or prepaying more than one month?
10. What is the cancellation deadline?
11. What happens if the clinician does not prescribe? Which charges are refunded?
12. What patient-specific medical reason will be documented for using a compounded dosage form?

If a company will not answer 4, 6, or 12 in writing, that is your answer.

How to check the pharmacy in five minutes

1. Copy the pharmacy's exact legal name.
2. Open your state's board of pharmacy license lookup.
3. Confirm the license is active.
4. Confirm the address matches the company you were given.
5. Confirm the pharmacy can legally ship into your state.
6. When the package arrives, compare the label with the pharmacy name you were promised.
7. Contact the prescriber before using it if the label names a different or unknown facility.

That last step is not paranoia. The FDA has warned about fraudulent compounded GLP-1 labels that name a pharmacy that does not exist or use the name of a real pharmacy that did not make the product.

Ten things that sound like proof and are not

• “FDA registered”
• “FDA-approved pharmacy”
• “Made in the USA”
• “Doctor approved”
• “Pharmacy grade”
• “The same compound”
• “Thousands of happy customers”
• “Clinically backed ingredients”
• A Trustpilot score
• A Better Business Bureau profile

A facility fact, review score, or marketing phrase cannot prove that a specific compounded oral product was absorbed, worked, or was made correctly.

What is not a red flag by itself

A page that calls everything dangerous helps nobody. None of these facts alone is a reason to walk away:

• An older inspection observation that was corrected
• A pharmacy declining to publish a proprietary formula
• A low price by itself
• One bad service review
• No PCAB accreditation; that accreditation is voluntary, not a federal requirement
• A telehealth company using a network of pharmacies instead of one
• A partly melted ice pack for a product that does not require frozen shipping

Look for a pattern: unnamed source, unsupported sameness claims, unclear first payment, rushed prescribing, contradictory terms, or a label that does not match what you were told.

Take the questions with you. Print this section or save the page as a PDF before you open a checkout. Write every answer beside the question. No email and no handoff required.

---

The biggest product-specific risk is uncertainty. Human absorption, dose behavior, average effectiveness, and long-term safety have not been established for the commercial oral forms in this register. Separately, the FDA had received more than 730 adverse-event reports associated with compounded tirzepatide as of May 31, 2026, but the agency warns that the reports are incomplete and do not prove the compound caused each event.

The measurement problem

For a specific tablet, you do not know:

• How much tirzepatide reaches the blood
• How fast the level rises or falls
• Whether one pharmacy's product behaves like another's
• What average weight change to expect
• What the product-specific long-term side-effect rate is
• How the oral dose relates to any studied injection dose

That is six unknowns on a product often taken every day.

The reporting gap

A traditional state-licensed 503A pharmacy does not have the same explicit federal adverse-event reporting duty that applies to a registered 503B outsourcing facility. Reports can still reach the FDA through patients, clinicians, companies, states, or voluntary pharmacy reporting, but the number is not a full count.

The FDA also says many reports do not contain enough information to determine whether a compounded product caused the event. Both facts matter:

• 730-plus is not a complete total.
• 730-plus is not proof that every event was caused by compounded tirzepatide.

Use the number as a safety signal, not a verdict.

What the clinician needs to know

Tell the clinician about:

• A personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• A serious allergic reaction to tirzepatide or another GLP-1 drug
• Pregnancy, breastfeeding, or plans to become pregnant
• Pancreatitis or gallbladder disease
• Serious stomach or bowel problems
• Kidney problems or dehydration risk
• Diabetes medicines, especially insulin or sulfonylureas
• Any surgery, anesthesia, or deep sedation coming up
• Any medicine where delayed stomach emptying or absorption matters

FDA-approved tirzepatide has a boxed warning about thyroid C-cell tumors seen in rats. It is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN 2. A compounded dosage form does not erase molecule-level warnings, and it may add ingredients with their own risks or instructions.

Read the label the pharmacy sends. Strut's lozenge includes vitamin B6, for example. Do not assume every product in this register contains only tirzepatide.

Contact your prescriber instead of a sales chat if something feels wrong. Severe stomach pain that will not stop, repeated vomiting, signs of dehydration, trouble breathing, facial swelling, or another severe reaction needs prompt medical care.

---

Skip compounded tirzepatide tablets if FDA approval, human evidence, insurance coverage, or knowing the dispensing pharmacy is non-negotiable. Also skip a provider that will not perform a real medical review, name the pharmacy, explain the exact first charge, or document why a compounded form is needed for you.

We would rather lose you here than have you lose $891.

Choose a different path if:

• You need an FDA-approved medicine
• You want results based on trials of the exact dosage form
• Your insurance covers an approved treatment
• You are willing to use one weekly injection once you compare the tradeoff
• The provider will not name the pharmacy before charging you
• The provider uses injection results to sell a tablet
• You cannot afford to lose a multi-month prepayment
• You need a simple cancellation path
• You are trying to get tirzepatide without a prescription
• No clinician can explain why a compounded oral form is needed for you
• The page contradicts itself about FDA approval, schedule, dose, or refund terms

If three or more describe you, the tablet is probably not your answer. That is not a lecture. It is the whole reason we built the register.

If FDA approval matters most, stop here and go straight to the options that have it.

→ Compare the FDA-approved pills and tirzepatide injection

---

Two FDA-approved GLP-1 tablets are available for chronic weight management: Foundayo, which contains orforglipron, and the Wegovy tablet, which contains semaglutide. Neither contains tirzepatide. FDA-approved tirzepatide remains an injection. Foundayo medicine starts at $149 through Lilly's self-pay program, while a Ro plan starts at $188 for the first month before tax or fees after adding Ro's $39 first-month membership.

This is the part more pages should lead with.

Foundayo — the pill you may have been looking for

Here is the fact that reframes the whole search:

The company that makes tirzepatide makes an FDA-approved GLP-1 tablet. The tablet is not tirzepatide.

The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1, 2026 for long-term weight reduction in adults with obesity or adults with overweight plus at least one weight-related condition, together with diet and activity.

It is a small-molecule GLP-1 receptor agonist taken once a day. It does not have to be taken on an empty stomach. That is a major practical difference from oral semaglutide.

The FDA approved it 50 days after filing under the Commissioner's National Priority Voucher program. It was the first new molecular entity approved under that program and the fastest new-molecule approval since 2002.

Lilly self-pay prices verified August 11, 2026:

The current $299 offer on the two highest doses requires an eligible refill within 45 days of the last delivery. Terms can change. The commercially insured savings card advertises a price as low as $25 per month for eligible covered patients, with caps and exclusions.

What Foundayo costs through Ro

Ro is a telehealth and support service. Its fee is separate from the medicine:

• $39 for the first month
• $149 a month on the monthly plan after that
• $99 a month on a three-month plan paid upfront
• $89 a month on a six-month plan paid upfront
• $74 a month on a twelve-month plan paid upfront

That means the lowest Ro first-month total for Foundayo is $188 before tax or fees: $39 for Ro plus $149 for the 0.8 mg medicine. A later month on the monthly Ro plan at the same medicine dose would be $298 before tax or fees.

Do not compare a drug-only LillyDirect price with an all-in telehealth price and call them the same deal. They solve different parts of the purchase.

The Wegovy tablet

The FDA approved the Wegovy tablet on December 22, 2025. It contains semaglutide, not tirzepatide.

The starting dose is 1.5 mg. The labeled maintenance dose is 25 mg. The tablet must be taken in the morning on an empty stomach with no more than 4 ounces of plain water, then you wait at least 30 minutes before food, drinks, or other oral medicines.

Ro medicine prices verified August 11, 2026:

Ro's membership is added to those medicine prices.

The honest tradeoff: the Wegovy tablet has human evidence and FDA approval, but the morning routine is strict. For some people, that routine is easy. For others, one weekly injection is simpler.

Zepbound — when tirzepatide itself is the requirement

If the molecule is non-negotiable, the injection is the only FDA-approved tirzepatide with human weight-loss evidence.

Lilly's current self-pay offer lists:

• 2.5 mg: $299 per month
• 5 mg: $399 per month
• 7.5 mg through 15 mg: $449 per month when current refill terms are met

Without the offer, regular self-pay prices can reach $499 for 7.5 mg and $699 for 10 mg through 15 mg. Check the live terms before paying.

With eligible commercial insurance coverage, a manufacturer savings card may reduce the cost further. Government insurance beneficiaries are generally excluded from commercial savings cards.

Approved and compounded options, side by side

Our damaging admission about Ro

We are going to be straight with you.

Ro does not sell a compounded tirzepatide tablet. If that exact product is the only thing you will accept, Ro cannot give it to you. Use the 12 questions and the provider register instead.

Ro also costs more than the medicine-only price because it charges for telehealth care and support. The $149 Foundayo headline becomes at least $188 in month one through Ro. On Ro's monthly plan, a later month at the lowest Foundayo dose would total $298 before tax or fees.

But the reason Ro earns the main approved-option link is simple: it offers the medicines that remove the biggest unknown in this article. You get an FDA-approved package, human evidence, a labeled dose, a public manufacturer price, and insurance support. You do not have to guess which pharmacy invented an oral route or whether an injection trial applies to it.

You were right that a GLP-1 pill exists. You were one molecule off.

Foundayo is FDA-approved, once daily, and has no empty-stomach rule. The medicine starts at $149, and a Ro plan starts at $188 for the first month before tax or fees.

→ See whether Foundayo is an option through Ro

Ro charges a separate membership. Medication is billed separately. Eligibility, prescribing, insurance coverage, savings offers, and state availability vary.

Want the full brand comparison before choosing a service? Compare FDA-approved GLP-1 pills and injections.

---

No appetite change, no side effects, or no weight loss cannot prove that a product was fake or that nothing entered your blood. It does tell you not to raise the dose, double up, or switch products on your own. Contact the prescriber, check the billing deadline today, document the product and pharmacy, and report a suspected problem to FDA MedWatch.

You are not the only person asking this. Do these four things:

1. Talk to a clinician before changing anything

Use the prescriber, your regular clinician, or a pharmacist who can see the label. Do not take more because you “felt nothing.” There is no validated oral-to-injection conversion.

2. Check the billing terms today

Find the exact cancellation date. Ask:

• Is another charge pending?
• Is an unfilled refill cancellable?
• Is any multi-month prepayment refundable?
• Did the company promise a refund if the clinician did not approve treatment?
• Which fee is nonrefundable?

Get the answer in writing before the next charge.

3. Save the evidence and report a suspected problem

Photograph the front and back of the bottle, the lot number, beyond-use date, strength, directions, pharmacy name, package, and receipt. Keep messages with the provider.

FDA MedWatch accepts consumer reports about quality problems and adverse events. A report does not accuse the company of a crime. It gives regulators information they may not receive from a traditional 503A pharmacy.

4. Check the seller's public record

Look for:

• An FDA warning letter
• A state board action against the dispensing pharmacy
• A pharmacy name that does not match the label
• A seller named in allegations in the Day complaint

A lawsuit allegation is not proof. A warning letter is not a recall. But either may tell you what questions to ask before another charge.

If the route itself is the problem, compare the approved tablets before paying again. Foundayo medicine begins at $149, while a Ro plan begins at $188 for month one before tax or fees.

→ Compare approved GLP-1 routes before paying again

---

Eli Lilly's current public development pipeline does not list an oral-tirzepatide program. Lilly's approved oral GLP-1 is Foundayo, which contains orforglipron, a different molecule built for oral use. There is no announced FDA filing or launch date for a true tirzepatide pill.

What is actually in the oral GLP-1 pipeline:

• Foundayo (orforglipron) — FDA-approved and available now
• The Wegovy tablet (semaglutide) — FDA-approved and available now
• Oral VK2735 from Viking Therapeutics — an investigational dual GLP-1/GIP drug; it is not tirzepatide and is not FDA-approved
• Lexaria's DehydraTECH work — an early delivery-platform study; not approved and not used by the providers in this register
• A true oral tirzepatide from Lilly — not listed in Lilly's current public pipeline

Could that change? Yes. Pipelines change. But today there is no countdown to a real tirzepatide pill. Waiting for an unannounced product is not a treatment plan.

---

We scored public transparency: how many buying facts a shopper can verify before paying. We did not score effectiveness, safety, or medical quality because the commercial dosage forms have no peer-reviewed human study. FDA letters, claim conflicts, and price contradictions stay separate from the score. A provider can publish seven facts and still make a claim that should stop you.

The eight points

One point for each fact published clearly on a current public page:

1. Exact dosage form
2. Current price
3. First payment or commitment
4. What the price includes
5. Dispensing pharmacy name
6. State availability
7. Cancellation or refund path
8. Clear disclosure that the compounded finished drug is not FDA-approved

The flags

• ⚑ FDA warning letter
• ⚑ Unsupported route-specific result or sameness claim
• ⚑ Price or term contradiction
• ⚑ Pharmacy not named
• ⚑ Checkout verification required
• ⚑ No human evidence for the commercial route

A transparency score is not a recommendation score. It only says what you can see before paying.

Our evidence labels

• Officially verified — supported by an FDA record, approved label, court filing, trial registry, or state record
• Provider-stated — published by the provider but not independently proved
• Calculated — our arithmetic from published numbers
• Conflicting — the provider's own pages disagree
• Unresolved — the public record did not answer it

Our source order

FDA approvals and labels → FDA policy and warning letters → ClinicalTrials.gov → PubMed → court records → state pharmacy boards → pharmacy pages → provider price, legal, state, and cancellation pages → independent reviews for service themes only → forums for buyer vocabulary only, never medical evidence.

Our rules

• No effectiveness score for a dosage form with no peer-reviewed human evidence
• No “safest” ranking without product-specific evidence
• No provider wins because it pays us
• An unnamed pharmacy is a real deduction
• A warning letter stays visible
• A low monthly average does not beat a low day-one payment automatically
• A temporary intro price is labeled as an intro price
• A drug-only manufacturer price is not treated as an all-in telehealth price
• FDA approval or exact-route human evidence wins when that is the reader's requirement

How we make money

Some providers pay us a commission when a reader uses a link. It costs the reader nothing extra. MEDVi is an affiliate partner and is not recommended here. Ro may also compensate us. Neither relationship changes the price fields, warning-letter fields, evidence standard, or final verdict.

Read our full ranking method and our corrections.

---

Does tirzepatide come in a pill?

Not as an FDA-approved product. FDA-approved tirzepatide is sold as Zepbound and Mounjaro injections. Telehealth companies sell compounded oral forms, but the finished products are not FDA-approved and the commercial routes in this register have no peer-reviewed human absorption or weight-loss study.

GLP-1 providers that offer tirzepatide tablets: the full list

As of August 11, 2026, we verified live public pages from Lavender Sky Health, Strut Health, Curex, GoodGirlRx, PlexusDx, Fitish RX, Henry Meds, SkinnyRx, MEDVi, Emerge Weight Loss, NexLife, Zealthy, Willow, TelehealthFX, Remote Pharmacy, Tru2U, Revel Health, and DietDoc.

Is oral tirzepatide FDA-approved?

No. No tirzepatide tablet, capsule, ODT, lozenge, troche, or drop is FDA-approved.

Is compounded oral tirzepatide legal?

It may be when a licensed prescriber writes a patient-specific prescription and the prescriber, compounder, ingredients, product, and medical need meet all federal and state rules. A product being sold online does not prove that a specific prescription meets those rules.

Do tirzepatide tablets work?

There is no reliable product-wide answer. We found no peer-reviewed human study of the commercial forms in this register. One company studied tirzepatide with a patented delivery system not claimed by these providers; its small company-reported tirzepatide arm did not show average weight loss over 12 weeks.

Is an ODT the same as a sublingual tablet?

Not always. An ODT is designed to disintegrate in the mouth. A sublingual product is meant to be held under the tongue. A buccal product is held against the cheek. Follow the pharmacy label, not a general sales page.

Can I swallow a tirzepatide ODT?

Use only the instructions on the pharmacy label. Ask the pharmacist or prescriber if the directions are unclear. This page does not give administration instructions.

How much do tirzepatide tablets cost?

A clear one-month or first-month charge runs from $149 to $699 in this register. Multi-month prepayment can reach $3,492. The number that matters is the amount charged today, the renewal amount, and the cancellation deadline.

What is the cheapest tirzepatide tablet provider?

Emerge Weight Loss has the lowest clear ongoing starting plan we verified at $149 for 30 ODTs. Revel Health also advertises $149 for the first month, then from $199. Curex says “from $199,” but its exact checkout terms remain unresolved.

Which provider names its pharmacy?

Lavender Sky Health has the clearest public disclosure in this register. It names Empower for the ODT and Strive for the sublingual product and publishes pharmacy-specific pricing.

Does insurance cover compounded oral tirzepatide?

Usually not. These programs are generally cash-pay. Insurance may cover an FDA-approved GLP-1, depending on the diagnosis, plan, formulary, prior-authorization rules, and exclusions.

Can I use an HSA or FSA?

Some providers accept HSA or FSA cards. Card acceptance does not guarantee the expense is eligible under your plan. Ask the plan administrator and keep the prescription and receipt.

Do I need a prescription?

Yes. A legitimate compounded tirzepatide program requires a licensed prescriber and a licensed pharmacy. “No prescription needed” is a serious red flag.

How do I find the pharmacy?

Ask for the exact legal name before paying. Check it in your state's board of pharmacy license lookup. When the package arrives, make sure the label matches the name you were given.

Is Foundayo the tirzepatide pill?

No. Foundayo contains orforglipron, not tirzepatide. Eli Lilly makes both medicines, but they are different molecules. Foundayo is an FDA-approved daily tablet and does not require an empty stomach.

Is the Wegovy tablet oral tirzepatide?

No. The Wegovy tablet contains semaglutide. It is FDA-approved and has a morning empty-stomach rule.

How much does Foundayo cost?

Lilly's self-pay program starts at $149 per 30 days for 0.8 mg. Higher doses cost more. Through Ro, the lowest first-month total starts at $188 before tax or fees after adding Ro's $39 first-month membership.

Can I switch from Zepbound to a compounded tablet?

Only a clinician who knows your history should make that decision. There is no validated conversion from injected tirzepatide to a compounded oral dose. Do not use a website conversion chart or change the dose yourself.

Does an FDA warning letter mean the company is shut down?

No. A warning letter is a formal notice about cited violations. It is not a recall, shutdown, or final judgment. It still belongs in a buying decision, especially when the cited issue is the exact marketing claim being used to sell the product.

What if a provider will not name the pharmacy?

Do not pay for the medicine until you know the source well enough to verify it. A provider may use more than one pharmacy, but it should be able to name the pharmacy assigned to your order before the drug charge.

Can I buy tirzepatide tablets without a prescription?

Do not use a site that offers human-use tirzepatide without a prescription. “Research use only” language does not make human dosing safe or legal.

Which option is best if I hate needles?

Three paths are real: an FDA-approved tablet such as Foundayo or the Wegovy tablet; a patient-specific compounded oral option with the unknowns accepted; or the FDA-approved weekly tirzepatide injection if the molecule matters more than the needle. Start with the requirement you will not compromise.

What side effects can GLP-1 medicines cause?

Approved labels commonly list stomach and bowel effects such as nausea, diarrhea, vomiting, constipation, and abdominal pain. Product warnings vary by molecule. Tirzepatide and other approved GLP-1 medicines also carry serious warnings and precautions. Review the exact medicine and your history with a clinician.

What should I do if I bought tablets and nothing happened?

Do not raise the dose on your own. Contact the prescriber, check the cancellation deadline, photograph the label and lot information, verify the pharmacy, and report a suspected quality problem or adverse event to FDA MedWatch.

---

Eighteen telehealth programs had a live oral-tirzepatide page when we checked. Every product in the register is compounded. None is an FDA-approved tirzepatide tablet. We found no peer-reviewed human study of the plain commercial ODTs, lozenges, sublingual tablets, or capsules.

If you buy one anyway, start with the pharmacy name, not the brand name. Avoid a four-figure prepayment for a product you have never used. Get the day-one charge, renewal price, cancellation date, exact dosage form, and medical reason in writing.

The lowest clear compounded plan we verified is $149 at Emerge. It is still an unapproved product with no route-specific human trial. The clearest pharmacy disclosure is Lavender Sky, but its lowest first payment is $360.

If what you wanted was an approved GLP-1 pill, the search ends differently. Foundayo is a real FDA-approved tablet. It is made by Eli Lilly. It is not tirzepatide. The medicine starts at $149 through Lilly's self-pay program, and a Ro plan starts at $188 for the first month before tax or fees.

You were not wrong to want a pill. You were one molecule off.

→ See whether Foundayo is an option through Ro

---

Still not sure which route fits you?

Start with four answers: your state, whether FDA approval is required, whether you will use an injection, and the most you can pay on day one.

→ Get a personalized GLP-1 action plan

---

FDA approvals, labels, safety, and compounding

• FDA: Foundayo approval announcement, April 1, 2026
• FDA-approved prescribing information for Foundayo (orforglipron tablets)
• FDA-approved prescribing information for Wegovy tablets (semaglutide)
• FDA-approved prescribing information for Zepbound (tirzepatide injection)
• FDA-approved prescribing information for Mounjaro (tirzepatide injection)
• FDA: Concerns with unapproved GLP-1 drugs used for weight loss
• FDA: FD&C Act provisions that apply to human drug compounding
• FDA: 30 telehealth companies warned over compounded GLP-1 marketing, March 3, 2026
• Strut Health warning letter 721448
• GoodGirlRx warning letter 721449
• Curex warning letter 716821
• Fitish warning letter 728280
• SkinnyRx warning letter 717989
• MEDVi warning letter 721455
• NexLife warning letter 730096
• Zealthy warning letter 716501
• FDA warning letter to Darmerica, including the agency's 503A discussion of retatrutide and cagrilintide

Manufacturer and telehealth pricing

• Foundayo coverage and self-pay terms
• Zepbound coverage and savings terms
• Ro weight-loss pricing
• Provider and pharmacy pages for Lavender Sky Health, Empower Pharmacy, Strive Pharmacy, Strut Health, Curex, GoodGirlRx, PlexusDx, Fitish RX, Henry Meds, SkinnyRx, MEDVi, Emerge Weight Loss, NexLife, Zealthy, Willow, TelehealthFX, Remote Pharmacy, Tru2U, Revel Health, and DietDoc, all accessed August 11, 2026

Research and pipeline

• PubMed search conducted August 11, 2026 for tirzepatide plus oral, sublingual, buccal, ODT, lozenge, troche, capsule, and rapid-dissolve terms
• ClinicalTrials.gov search conducted August 11, 2026
• ClinicalTrials.gov record NCT06648031, Lexaria DehydraTECH study
• Lexaria Bioscience company reports for the 2025 pilot and 2026 Phase 1b results; company-reported, not treated as peer-reviewed evidence
• Eli Lilly current clinical-development pipeline, accessed August 11, 2026
• Viking Therapeutics public trial and pipeline materials for oral VK2735

Courts

• Operative complaint in Day v. OpenLoop Health Inc. et al., allegations only
• Public docket for Day v. OpenLoop Health Inc. et al., No. 1:25-cv-01418
• Outsourcing Facilities Association v. FDA, N.D. Tex., order denying preliminary injunction, March 5, 2025

Outside pages audited for absorption claims

• formblends.com oral and sublingual tirzepatide pages
• peptidesexplorer.com oral-tirzepatide page
• seekpeptides.com oral-tirzepatide page
• PlexusDx oral-tirzepatide evidence page

Those pages are included to document what the market says, not as clinical proof.

---

August 11, 2026 — Full accuracy rebuild. Expanded the active register from 11 to 18 verified public programs; removed MyStart Health and Gala GLP-1 from the active seller count; added Emerge, NexLife, Zealthy, Willow, TelehealthFX, Remote Pharmacy, Tru2U, Revel Health, and DietDoc; corrected the cheapest short-plan finding from Strut to Emerge; added Revel's $149 intro; corrected GoodGirlRx's conflicting price pages; added all eight verified warning letters and separated Zealthy's semaglutide-only letter from the seven letters that mention tirzepatide; corrected Curex's conflicting state lists; removed unsupported oral-to-injection dose equivalents; added the registered DehydraTECH human study and its company-reported tirzepatide result; corrected 503A, 503B, and shortage-law language; narrowed the proposed class-action description to the named defendants and current public posture; corrected Foundayo, Wegovy tablet, Zepbound, LillyDirect, and Ro prices and terms; removed unverified testimonials, fake tools, dead links, and unsupported needle-free gum claims; preserved the first-payment ledger, damaging admissions, provider warnings, decision architecture, and conversion sequence.